PubMed · 1984 · 272 citations · 0 references
MedicineGynecologyObstetricsBenign Gynecologic DisordersCancer ScreeningGynecologic OncologyBenign Ovarian TumorsEarly Cancer DetectionOvarian CancerOvarian NeoplasiaTumor AntigensTumor MarkersCancer Antigen 125Ovarian Cancer DetectionOvarian Cancer Early DetectionOvarian Cancer ScreeningOvarian Neoplasm DetectionOvarian Tumor Biomarkers
An immunoradiometric assay using a monoclonal antibody detects an antigenic determinant (CA125) that is present in more than 80% of epithelial ovarian cancers. CA125 levels are elevated in the sera of 16% of women in the first trimester of pregnancy and is found in very high concentration in amniotic fluid. In 988 nonpregnant patients with benign gynecologic disorders, CA125 was greater than 65 U/mL in 1% on a single determination and in 0.5% with two determinations. Given the low rate of positivity in benign gynecologic disease, the CA125 assay may deserve further evaluation for the early detection of ovarian carcinoma.